



Study
ID

OR (95% CI)

1 anthracycline (a) v non-anthracycline (b)




2 anthracycline (a) v mitoxantrone (b)




3 bolus (a) v continuous (b)




4 epirubicin (a) v doxorubicin (b)



5 liposomal doxorubicin (a) v doxorubicin (b)



7 cardioprotective agent (a) v none (b)



.01 .1 2 1 5 10 100

Favours a Favours b